15th Apr 2024 14:12
(Alliance News) - Ondine Biomedical Inc on Monday reported that a study undertaken at the Mazankowski Alberta Heart Institute demonstrated a 32% reduction in cardiac surgical site infections through the use of its Steriwave product as a replacement for the antibiotic Mupirocin.
This comes after Steriwave was implemented on a pilot basis as a replacement for Mupirocin in June last year, the Vancouver-based life sciences company said.
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, SSIs are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
Just last week, Ondine announced that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Shares in Ondine were up 1.0% at 7.57 pence each in London on Monday afternoon.
By Sabrina Penty, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.